Novabay Pharmaceuticals earnings were $2.3M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest NBY earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$1.9M, down 125.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, NBY reported annual earnings of -$8.6M, with -49.3% growth.
Novabay Pharmaceuticals Earnings Reports & History FAQ
What were Novabay Pharmaceuticals's earnings last quarter?
Novabay Pharmaceuticals (NYSEMKT: NBY) reported Q2 2025 earnings per share (EPS) of -$0.33, up 75.91% year over year. Total NBY earnings for the quarter were -$1.92 million. In the same quarter last year, Novabay Pharmaceuticals's earnings per share (EPS) was -$1.37.
Is Novabay Pharmaceuticals profitable or losing money?
As of the last Novabay Pharmaceuticals earnings report, Novabay Pharmaceuticals is currently profitable. Novabay Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $3.32 million, a 130.4% decrease year over year.
What was NBY's earnings growth in the past year?
As of Novabay Pharmaceuticals's earnings date in Q3 2025, Novabay Pharmaceuticals's earnings has grown year over year. NBY earnings in the past year totalled $2.32 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.